<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084990</url>
  </required_header>
  <id_info>
    <org_study_id>201908162</org_study_id>
    <nct_id>NCT04084990</nct_id>
  </id_info>
  <brief_title>Sleep Apnea and Fetal Growth Restriction</brief_title>
  <acronym>SAFER</acronym>
  <official_title>Sleep Apnea and Fetal Growth Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ResMed Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hebrew University Hadassah Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the association between obstructive sleep apnea (OSA) and fetal&#xD;
      growth restriction (FGR) and to assess the role of auto-titrated positive airway pressure&#xD;
      (aPAP) as antenatal therapy in these patients. Pregnant patients with diagnosed FGR will be&#xD;
      screened for OSA first by screening questionnaire and then by home sleep monitor. Of those&#xD;
      patients diagnosed with OSA, half will be assigned to use aPAP each night when sleeping and&#xD;
      half will not (standard care).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fetal growth restriction (FGR) affects 5-10% of pregnancies and is one of the leading causes&#xD;
      of perinatal morbidity and mortality.&#xD;
&#xD;
      Obstructive sleep apnea (OSA) is a common disorder in which a person's breathing pauses or&#xD;
      becomes shallow during sleep. These periods of low oxygen lead stress and inflammation which&#xD;
      that may be harmful to both the mother and her fetus. OSA in pregnancy has been associated&#xD;
      with poor maternal-fetal outcomes, including low birth weight, preterm delivery, FGR,&#xD;
      gestational hypertension/preeclampsia, gestational diabetes and higher rates of neonatal ICU&#xD;
      admission.&#xD;
&#xD;
      Auto-titrated positive airway pressure (aPAP) is a machine that gently delivers pressurized&#xD;
      air via a mask to keep a patient's airways free of obstruction during sleep. It is currently&#xD;
      unclear whether treatment of OSA during pregnancy in women with known FGR can improve fetal&#xD;
      and neonatal outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, parallel group, investigator-blinded, randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Birth weight</measure>
    <time_frame>1 day</time_frame>
    <description>Weight of child at time of birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>1 day</time_frame>
    <description>Gestational age at delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Fetal Growth Restriction</condition>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>aPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nightly use of aPAP when sleeping through the date of delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No aPAP</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No use of aPAP (standard of care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>S9 VPAP Adapt</intervention_name>
    <description>Auto-titrated positive airway pressure</description>
    <arm_group_label>aPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 50&#xD;
&#xD;
          -  Fetal growth restriction (defined as fetal weight &lt;10th percentile based on at least&#xD;
             one routine 2nd trimester ultrasound without a subsequent increase to &gt;15th percentile&#xD;
             on any ultrasounds prior to enrollment)&#xD;
&#xD;
          -  Lower limit of gestational age at enrollment 22+0 weeks.&#xD;
&#xD;
          -  Upper limit of gestational age at enrollment: adequate time to complete Stages 1 and 2&#xD;
             and if appropriate to be randomized and receive intervention by no later than 32+0&#xD;
             weeks.&#xD;
&#xD;
          -  The absence of 2 minor or 1 major markers of aneuploidy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other known cause of fetal growth restriction (including congenital anomalies,&#xD;
             intrauterine infection, or multiple gestation)&#xD;
&#xD;
          -  Reversed end-diastolic flow in the umbilical artery&#xD;
&#xD;
          -  Preexisting diagnosis of OSA being treated with aPAP&#xD;
&#xD;
          -  Chronic pulmonary disease (cystic fibrosis, moderate persistent asthma)&#xD;
&#xD;
          -  Hemoglobinopathies (sickle cell anemia, thalassemia)&#xD;
&#xD;
          -  Maternal craniofacial anomalies&#xD;
&#xD;
          -  Premature rupture of membranes&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Hincker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University in Saint Louis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Hincker, MD</last_name>
    <phone>314-362-2628</phone>
    <email>hinckera@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ellen Lockhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rochester University Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Hebrew University</name>
      <address>
        <city>W. Jerusalem</city>
        <state>Jerusalem</state>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yehuda Ginosar, MBBS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nardozza LM, Caetano AC, Zamarian AC, Mazzola JB, Silva CP, Marçal VM, Lobo TF, Peixoto AB, Araujo Júnior E. Fetal growth restriction: current knowledge. Arch Gynecol Obstet. 2017 May;295(5):1061-1077. doi: 10.1007/s00404-017-4341-9. Epub 2017 Mar 11. Review.</citation>
    <PMID>28285426</PMID>
  </reference>
  <reference>
    <citation>Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia--revisited--the bad ugly and good: implications to the heart and brain. Sleep Med Rev. 2015 Apr;20:27-45. doi: 10.1016/j.smrv.2014.07.003. Epub 2014 Jul 24. Review.</citation>
    <PMID>25155182</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 7, 2019</study_first_submitted>
  <study_first_submitted_qc>September 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Alexander M. Hincker</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>aPAP</keyword>
  <keyword>OSA</keyword>
  <keyword>FGR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

